IL17C抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane 1-4: A549 cells, K562 cells, Raji cells, human fetal intestine tissue, Primary antibody: P04959(IL17C Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gasrtic cancer tissue using P04959(IL17C Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P04959(IL17C Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

IL-17C, a member of the IL-17 cytokine family, is implicated in inflammatory and autoimmune diseases. Unlike other IL-17 family members (e.g., IL-17A/F), IL-17C is primarily expressed by epithelial and barrier tissues in response to pathogens or tissue damage. It binds to a heterodimeric receptor complex (IL-17RA/RE) to activate downstream pro-inflammatory pathways, including NF-κB and MAPK signaling, leading to the production of cytokines, chemokines, and antimicrobial peptides. Dysregulated IL-17C signaling has been linked to chronic inflammatory conditions such as psoriasis, asthma, inflammatory bowel disease (IBD), and atopic dermatitis.

IL-17C-targeting antibodies are therapeutic agents designed to block IL-17C activity. By inhibiting IL-17C binding to its receptor, these antibodies aim to suppress pathological inflammation while preserving other IL-17-mediated protective immune functions. Preclinical studies in murine models demonstrated efficacy in reducing disease severity in psoriasis-like skin inflammation and colitis. Clinical trials of anti-IL-17C antibodies (e.g., MOR106) have shown mixed results, with some trials halted due to insufficient efficacy, highlighting the complexity of IL-17C's role across different diseases.

Current research focuses on identifying patient subpopulations with IL-17C-driven pathology and optimizing antibody design for enhanced specificity. Safety concerns, including potential immunosuppression risks, remain under investigation. IL-17C antibodies represent a promising but challenging avenue for targeted immunomodulation in epithelial-driven inflammatory disorders.